Statements (79)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:biotechnology
|
| gptkbp:acquisition |
gptkb:Merck_&_Co.
|
| gptkbp:advances |
innovative solutions
|
| gptkbp:biologics_license_application |
in progress
|
| gptkbp:biopharma_sector |
active participant
|
| gptkbp:biopharmaceutical_innovations |
new drug development
|
| gptkbp:biopharmaceutical_research |
leading-edge science
|
| gptkbp:biotech_community |
active member
|
| gptkbp:biotech_innovation |
cutting-edge research
|
| gptkbp:biotech_landscape |
emerging player
|
| gptkbp:business_model |
biopharmaceutical development
|
| gptkbp:ceo |
gptkb:Pankaj_S._Desai
|
| gptkbp:clinical_advancements |
new treatment options
|
| gptkbp:clinical_trial |
gptkb:pharmaceuticals
ongoing studies various phases positive results Phase 2 studies Phase 3 trial for COVID-19 promising data |
| gptkbp:clinical_use |
experienced researchers
|
| gptkbp:collaboration |
academic institutions
|
| gptkbp:collaborations |
academic partnerships
biopharma companies multi-disciplinary teams |
| gptkbp:community_engagement |
patient advocacy
|
| gptkbp:focus |
gptkb:immunotherapy
|
| gptkbp:founded |
gptkb:2015
|
| gptkbp:founder |
gptkb:Pankaj_S._Desai
|
| gptkbp:funding |
Series A funding
grants and investments various investors |
| gptkbp:has_advisory_board |
experts in immunology
|
| gptkbp:headquarters |
gptkb:Rockville,_Maryland
|
| gptkbp:healthcare |
Fast Track designation
advanced therapies new treatment modalities leading initiatives |
| gptkbp:healthcare_advancements |
improved therapies
|
| https://www.w3.org/2000/01/rdf-schema#label |
Onco Immune
|
| gptkbp:initiatives |
focused studies
|
| gptkbp:instruction_set |
multiple drug candidates
|
| gptkbp:invention |
patents filed
|
| gptkbp:investment |
Venture capital firms
biotech sector |
| gptkbp:is_a_platform_for |
immune modulation
|
| gptkbp:leadership |
experienced management team
|
| gptkbp:marketing_strategy |
expansion plans
|
| gptkbp:mission |
develop innovative therapies
|
| gptkbp:notable_technology |
novel therapies
|
| gptkbp:partnership |
gptkb:National_Institutes_of_Health
|
| gptkbp:partnerships |
research institutions
strategic alliances collaborative efforts |
| gptkbp:patient-centric_approach |
focus on patient needs
|
| gptkbp:product |
Onco Immune's lead product candidate
pipeline advancement |
| gptkbp:reach |
international collaborations
|
| gptkbp:regulatory_compliance |
FDA submissions
|
| gptkbp:research |
peer-reviewed publications
|
| gptkbp:research_areas |
gptkb:cancer_treatment
infectious diseases cutting-edge therapies immune system modulation strategic focus various indications |
| gptkbp:research_focus |
patient safety
autoimmune diseases novel immunotherapies |
| gptkbp:side_effect |
transforming treatment paradigms
|
| gptkbp:technology |
T cell therapy
|
| gptkbp:therapeutic_pipeline |
diverse candidates
|
| gptkbp:treatment |
improved patient outcomes
enhanced quality of life |
| gptkbp:vision |
transform patient care
|
| gptkbp:website |
www.oncoimmune.com
|
| gptkbp:bfsParent |
gptkb:Merck
gptkb:Biogen_Idec |
| gptkbp:bfsLayer |
5
|